Singapore markets closed
Straits Times Index
3,217.41 +10.42 (+0.32%) Nikkei
31,857.62 -14.90 (-0.05%) Hang Seng
17,809.66 +436.63 (+2.51%) FTSE 100
7,608.08 +6.23 (+0.08%) Bitcoin USD
27,133.37 +138.08 (+0.51%) CMC Crypto 200
579.66 +0.90 (+0.15%)
Cellectis S.A. (CLLS)
NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 1.5800 |
| Open | 1.5800 |
| Bid | 0.0000 x 1000 |
| Ask | 1.5900 x 1400 |
| Day's range | 1.5800 - 1.5900 |
| 52-week range | 1.5800 - 4.0400 |
| Volume | |
| Avg. volume | 50,444 |
| Market cap | 87.822M |
| Beta (5Y monthly) | 1.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
- Reuters
French biotech Cellectis takes stake in Mayflower-backed startup Primera
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
ZacksIovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
- Zacks
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
© 2023 Yahoo. All rights reserved.
